Naltrexone is NOT Recommended for Fibromyalgia Treatment
Naltrexone should not be used to treat fibromyalgia. The most recent high-quality evidence from 2026 demonstrates that low-dose naltrexone (LDN) provides no clinically meaningful benefit over placebo for fibromyalgia symptoms 1. This directly contradicts earlier small pilot studies and is further supported by current clinical practice guidelines that do not include naltrexone among recommended fibromyalgia treatments.
Why Naltrexone Should Be Avoided
The 2022 CDC guidelines explicitly recommend FDA-approved medications for fibromyalgia: duloxetine, milnacipran, and pregabalin 2. These are the evidence-based first-line pharmacologic options. The 2017 EULAR guidelines similarly recommend SNRIs (duloxetine, milnacipran) and anticonvulsants (pregabalin, gabapentin) but make no mention of naltrexone 3.
The INNOVA study (2026), a 12-month randomized controlled trial in 98 women with fibromyalgia, found that LDN 4.5 mg daily produced only a 0.33-point reduction in pain compared to 0.64-point reduction with placebo—a statistically insignificant difference (p=0.236) 1. Response rates were similarly low and comparable between groups. A 2025 meta-analysis confirmed these findings, showing no significant difference between LDN and placebo for pain (SMD -0.50,95% CI: -1.19 to 0.19) or symptom severity 4.
The Evidence Trajectory Shows Declining Efficacy
While early pilot studies from 2009-2013 suggested potential benefit 5, 6, these were small crossover trials with significant methodological limitations. The 2013 study showed 28.8% pain reduction versus 18% with placebo 5, but this was in only 31 patients. As study quality and size improved, the apparent benefit disappeared entirely 1, 7, 4.
What Should Be Used Instead
For fibromyalgia pharmacotherapy, follow this algorithm:
First-line options:
- Duloxetine 30 mg daily for 1 week, then 60 mg daily (FDA-approved) 2, 3
- Milnacipran 100-200 mg daily (FDA-approved) 3
- Pregabalin titrated to effective dose (FDA-approved) 2, 3
Second-line options:
- Gabapentin (titrate slowly due to nonlinear pharmacokinetics) 3
- Amitriptyline (use cautiously in adults >65 years due to anticholinergic effects) 2
- Topical diclofenac for localized pain 2
Avoid entirely:
- Strong opioids (no efficacy evidence, high addiction risk) 3
- Corticosteroids (no efficacy evidence) 3
- Naltrexone (no benefit over placebo in high-quality trials) 1, 4
Critical Contraindications If Naltrexone Were Considered
The FDA labeling makes clear that naltrexone is approved only for alcohol and opioid dependence, not pain conditions 8. If a clinician were to use it off-label despite the evidence against doing so:
Absolute contraindications:
- Current opioid use (naltrexone blocks opioid analgesia and precipitates withdrawal) 9, 10, 8
- Anticipated need for opioid analgesia (including procedures requiring fentanyl) 11
- Active opioid dependence without 7-10 days opioid-free (14 days for buprenorphine/methadone) 8
Monitoring requirements per FDA labeling:
- Baseline liver function tests 10, 8
- Repeat liver function tests every 3-6 months 10
- Higher hepatotoxicity risk at doses >50 mg 8
Dosing (if used off-label, which is not recommended):
- The pilot studies used 4.5 mg daily 1, 5, 6
- FDA-approved dosing for other indications: 50 mg daily 8
- Low-dose naltrexone (1-5 mg) is entirely off-label for any indication 12
Common Pitfalls to Avoid
- Do not rely on anecdotal case reports 13 when high-quality RCT evidence shows no benefit 1
- Do not assume "low-dose" means "low-risk"—naltrexone still blocks opioid receptors at any dose and causes insomnia, vivid dreams, and can increase pain 1, 7, 6
- Do not use naltrexone as a substitute for proven therapies—patients deserve treatments with demonstrated efficacy 2, 3
The evidence is clear: stick with FDA-approved medications that have consistent evidence of benefit in fibromyalgia management.